In-vitro activity of nitrofurantoin in Enterococcus urinary tract infection

Journal of the Pakistan Medical Association

Volumn 54, Issue 9, 2004, Pages 466-469

  Butt, T ^a   Leghari, M J ^a   Mahmood, A ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; COTRIMOXAZOLE; DOXYCYCLINE; IMIPENEM; NITROFURANTOIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; IN VITRO STUDY; NONHUMAN; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; PAKISTAN; SENSITIVITY AND SPECIFICITY; URINARY TRACT INFECTIONS;

EID: 6344277889     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Centers for Disease Control. National Nosocomial Infections Study Report, Atlanta: Centers for Disease Control, 1979, pp. 2-14.
2. Lifshit E, Kramer L. Outpatient urine culture: does collection technique matter? Arch Intern Med 2000;160:2537-40.
3. Lutters M, Vogt N. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. Cochrane Database of Syst Rev 2002;2:CD001535.
4. Orenstein R, Wong ES. Urinary tract infections in adults. Am Family Phys 1999;59:1225-34.
5. Huycke MM, Sahm DF, Gilmore MS. Multiple drug resistant enterococci: the nature of the problem and agenda for the future. Emerg Infect Dis 1998;4:239-49.
6. Farooqi B, Shareeq F, Rizvi Q, et al. Changing pattern of antimicrobial susceptibility of organisms causing community acquired urinary tract infections. J Pak Med Assoc 2000;50:369-73.
7. MacCallum WG, Hastings TW. A case of acute endocarditis caused by Micrococcus zymogenes, with a description of the microorganism. J Exp Med 1999;4:521-34.
8. Zerovos MJ, Schaberg DS. Reversal of the in-vitro susceptibility of enterococci to trimethoprim-sulphamethoxazole by folinic acid. Antimicrob agents Chemother 1985;28:446-8.
9. Murray BE. The life and time of enterococcus. Clin Microbiol Rev 1990;3:46-65.
10. Moellering RC Jr. Emergence of enterococcus as a significant pathogen, Clin Infect Dis 1992;14:1173-8.
11. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infections. Am J Med 1991; (Suppl 3B):72S-75S.
12. Spencer RC, Mosely DJ, Greensmith MJ. Nitrofurantoin modified release versus trimethoprim or co-trimoxazole in the treatment of uncomplicated urinary tract infection in general practice. J Antimicrob Chemother 1994;33:121-9.
13. Hooteon TM, Winter C, Tiu F, et al. Randomized comparative trial and cost analysis of 3day antimicrobials regimen for treatment of acute cystitis in women. JAMA 1995;273:41-3.
14. Iravani A, Klimberg I, Briefer C, et al. A trial comparing low-dose, short-course ciprofloxacin and standard 7-day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999;43 (Suppl. A):67-75.
15. Cunha BA. Nitrofurantoin: an update. Obstet Gynecol Surv 1989;44:399-406.
16. Edwards DI. Nitroimidazole drugs - action and resistance mechanisms I. Mechanism of action. J Antimicrob Chemother 1993;31:9-20.
17. Zhanel GG, Hoban DJ, Karlowsk JA. Nitrofurantoin is active against vancomycin resistant enterococci. J Antimicrob Chemother 2001;45:324-6.
18. Ferraro MJ, Craig WA, Dudley MN, et al. Performance standards for antimicrobial disc susceptibility tests. 7th ed. Approved standard M2-A7. Wayne Pa: National Committee for Clinical Laboratory Standards. 2000.
19. Tenover FC, Biddle JW, Lancaster MV. Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32.
20. Ferraro MJ, Craig WA, Dudley MN, et al. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2000.
21. Bonadio M, Meini M, Tagliaferri E, et al. Enterococcal glycopeptide resistance at an Italian teaching hospital. J Antimicrob Chemother 2000;46:129-31.
22. Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS). J Antimicrob Chemother 2003;52:382-8.
23. Brumfitt W, Hamilton-Miller JMT. Efficacy and Safety profile of long-term nitrofurantoin in urinary tract infections: 18 years' experience. J Antimicrobiol Chemother 1998;42:363-71.
24. Landman D, Quale JM. Management of infections due to resistant enterococci: a review of therapeutic options. J Antimicrobiol Chemother 1997;40:161-70.
25. Kauffman CA. Therapeutic and preventative options for the management of vancomycin-resistant enterococcal infections. J Antimicrobiol Chemother 2003;51(Suppl 3):iii23-iii30.